INTRODUCTION
The balance between inflammatory and regulatory factors is vital to prevent tissue damage during infection and in the control of detrimental responses to self-antigen. T helper 1 (Th1) and T helper 17 (Th17) cells promote inflammation through their production of cytokines such as interferon-g (IFN-g), interleukin-17 (IL-17), and IL-22. On the other hand, Foxp3
+ regulatory T cells control inflammation through multiple mechanisms including production of the cytokine IL-10 and transforming growth factor-b (TGF-b). TGF-b suppresses the putative Th1 cell transcription factor T-bet, as well as IFN-g production (Lin et al., 2005; Park et al., 2005) . TGF-b also promotes development and maintenance of Foxp3 + regulatory T cells (Marie et al., 2005) , and mice in which T cells cannot respond to TGF-b succumb to lethal inflammatory disease largely dominated by Th1 cells (Fahlen et al., 2005; Li et al., 2006 ). It was somewhat unexpected then that TGF-b, when combined with inflammatory cytokines such as IL-6, was shown to promote Th17 cell development at the expense of Treg cell development in vitro (Bettelli et al., 2006; Mangan et al., 2006; Veldhoen et al., 2006a) . However, the role of TGF-b in Th17 cell development remains controversial, particularly for human T cells (Boniface et al., 2008) . In addition to induction by TGF-b (with inflammatory cytokines acting as a switch factor), Treg and Th17 cell development share several other common themes. It has been suggested that the transcription factors Foxp3 and RORgt are concomitantly upregulated in developing Th17 cells by TGF-b and that further signals, such as IL-6 and IL-23, are required to prevent Foxp3 from suppressing RORgt expression (Zhou et al., 2008) . This scenario appears most relevant in the gut, where high concentrations of TGF-b regulate responses to commensal bacteria and T cells expressing both RORgt and Foxp3 are most readily found (Zhou et al., 2008) . In addition, cytokines that promote Th17 cell development (including IL-6 and TNF-a) inhibit the function of Treg cells to allow effector responses that are required during infection (Pasare and Medzhitov, 2003; Valencia et al., 2006) . In contrast, Treg cells are highly dependent on IL-2 for survival (Setoguchi et al., 2005) , whereas Th17 cell responses are inhibited by IL-2 (Laurence et al., 2007) .
The sources of TGF-b for Th17 cell induction remain unclear but there are suggestions that T cells and possibly Treg cells may be involved. In vitro, Foxp3 + regulatory T cells are a sufficient source of TGF-b for induction of demonstrated by the requirement for addition of exogenous TGF-b in Treg celldeficient cultures (LeibundGut-Landmann et al., 2007; Veldhoen et al., 2006a) . In vivo, Veldhoen and colleagues have used T cellrestricted TGF-b receptor (TGF-bR) deficiency to show that TGF-b acts directly on T cells for Th17 cell induction (Veldhoen et al., 2006b ). Furthermore, Li et al. (2007) restricted TGF-b deficiency to T cells to show that T cells are an important source of TGF-b in vivo. However, these studies do not define which T cell population produces TGF-b to promote Th17 cell induction nor whether this source is required throughout the response or only at certain stages of Th17 cell development. Furthermore, results are complicated by the large Th1 cell-mediated inflammatory responses that develop in these mice, because it is known that Th1 cell-related cytokines (IL-12, IFN-g) suppress Th17 cell development (McGeachy and Cua, 2008 ). The precise mechanisms of TGF-b signaling in Th17 cell development also remain unclear, and one recent report suggests that TGF-b functions indirectly to inhibit Th1 cell and Th2 cell responses (Das et al., 2009) , thereby facilitating the emergence of the Th17 cell phenotype.
Mice genetically deficient for functional Foxp3 expression develop lethal inflammatory disease at an early age (Fontenot et al., 2003; Khattri et al., 2003) , limiting their usefulness. We therefore used a model in which Foxp3-expressing T cells could be depleted in healthy adult mice. Foxp3.luciDTR mice carry a bacterial artificial chromosome transgene expressing Diphtheria toxin receptor (DTR), green fluorescent protein (GFP), and Click Beetle luciferase, under control of the Foxp3 promoter (Suffner et al., 2010) . Several lines of these mice were created with differing expression of the transgene. Foxp3.luciDTR4 mice deplete 90% to 95% of Foxp3 + cells after DT administration without any overt signs of ill health or weight loss, although immune activation is evident in lymphoid tissues (Suffner et al., 2010 (Suffner et al., 2010) . We hypothesized that the remaining 5%-10% could partially compensate to induce some IL-17. We therefore also tested the ability of Th17 OT-II cells to differentiate in Foxp3.luciDTR5 mice, which deplete >99% of Treg cells after DT administration (Suffner et al., 2010 
CD25
-cells, were cotransferred with OT-II cells, there was an enhanced IL-17 response compared to OT-II cells transferred alone ( Figure 1E ).
To test whether the reduced IL-17 that we observed when Treg cells were depleted correlated with functional changes, we used the delayed-type hypersensitivity (DTH) response as a functional readout. Mice in which Treg cells were depleted at time of immunization displayed a significantly reduced DTH response after challenge with ovalbumin in the footpad (Figure 1F ; Figure S1 available online). We also observed reduced frequencies of both total OT-II + cells and IL-17 + OT-II + cells in the blood of Treg cell-depleted mice compared to nondepleted (Figures 1G and 1H) , suggesting that the reduced DTH response was due to fewer Th17 cells available to enter peripheral tissue sites and establish inflammation. Taken together, these data suggested that the reduced IL-17 seen when OT-II cells were primed in the absence of Treg cells correlated with reduced inflammatory potential at the population level. Figure 2A ). However, percentages of all Foxp3 + cells
were not significantly different between untreated controls and mice that received DT at day À1, although they were still reduced in mice that received DT on days 2 and 4 postimmunization (Figure 2B) . These results correlated with the findings of Suffner et al. (2010) in nonimmunized mice: after DT administration, the remaining GFP-negative (and therefore DTR-negative) Foxp3 + cells undergo homeostatic expansion to replace their depleted GFP + counterparts. However, it appeared that in mice immunized with peptide in CFA, this expansion was accelerated, because the Treg cell population size had completely recovered by day 7 in our study, whereas in nonimmunized mice this recovery takes 2 weeks (Suffner et al., 2010) . Depletion of regulatory T cells on day 2 postimmunization led to reduced frequencies of IL-17 + OT-II cells analyzed on day 7, similar to results when Treg cells were depleted at the time of immunization ( Figure 2C ). However, depletion of Treg cells on day 4 had no effect on subsequent IL-17 production. Therefore, the data are consistent with a requirement for Treg cells during the initial activation of Th17 cells, but that after 4 days the presence of regulatory T cells no longer promotes Th17 cell development. Because there was also no increase in the frequency of IL-17 + cells in mice where Treg cell numbers were still low (comparing depletion on day 4 versus day À1), it seems that Treg cells are also not required to regulate late Th17 cell expansion.
To further investigate whether Treg cells promote long-term Th17 cell maintenance in vivo, we generated Th17 cells in vitro by activating OT-II T cells with OVA(323-339) in the presence of TGF-b, IL-6, anti-IFN-g, and anti-IL-2. This resulted in more than 70% of the T cells producing IL-17 ( Figure 2D ), and these cells were transferred into recipient Foxp3.luciDTR4 mice that were then immunized with OVA(323-339) in CFA to further activate the cells in the presence of inflammatory cytokines including IL-23. Depletion of Treg cells at the time of immunization did not have any effect on maintenance of IL-17 production ( Figure 2E ). In nonimmunized control mice, the overall frequencies of IL-17 + cells were lower compared to immunized mice, and the absence of Treg cells did result in a slight decrease in IL-17 production 7 days after transfer ( Figure 2F ). This suggested that there was a minimal requirement for Treg cells during later activation and All data shown are representative of two to three similar experiments with three to four mice per group; some data are pooled from multiple experiments; horizontal bars indicate mean.
Immunity
Treg Cells Promote Th17 Cells In Vivo through IL-2 maintenance of Th17 cells in vivo, particularly under inflammatory conditions, correlating with the finding that depleting Treg cells at day 4 postimmunization had little effect.
Th17 Cells Can Develop in the Presence of Highly Activated Regulatory T Cells
Homeostatic or activation-induced expansion of regulatory T cells is known to increase their activation state and ability to suppress (Gavin et al., 2002; Tarbell et al., 2004) . Indeed, Foxp3 + cells that had homeostatically expanded after DT administration had increased expression of the activation marker CD44 ( Figure 3A ), again confirming observations made in nonimmunized mice (Suffner et al., 2010 Figures 3D-3F ), suggesting reduced expansion of OVA-specific T cells. We therefore set out to test whether the LN environment that was generated when Treg cells were depleted at time of immunization contributed to the reduced IL-17 in OT-II cells. Wildtype and Foxp3.luciDTR4 mice were immunized as before with OVA(323-339) in CFA and received DT on day À1 and day 0. However, OT-II cells were not transferred until day 6 postimmunization. Thus, the Th17 cells were differentiated in the presence of either highly active recently expanded Treg cells or ''normal'' Treg cells (in nondepleted mice). Analysis on day 6 after transfer (day 12 postimmunization) showed that OT-II cells had expanded equally well in Foxp3.luciDTR4 and wild-type mice ( Figure 4A ), despite the presence of higher frequencies CD44 
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Treg Cells Promote Th17 Cells In Vivo through IL-2 (323-339) in CFA, then transferred OT-II cells 3 days later. Again, expansion of OT-II cells was comparable to recipients that were not subjected to Treg cell depletion ( Figure 4F) . Surprisingly, IL-17 production was enhanced in OT-II cells transferred into mice depleted of Treg cells 3 days earlier compared to controls ( Figure 4G ). These results suggested that Treg cell depletion did not inhibit IL-17 indirectly because of nonspecific bystander cell activation, but rather the activated environment and/or the presence of expanding Treg cells on day 3 postimmunization actually enhanced Th17 cell development. Th17 Cell Development Does Not Require Treg Cell-Produced TGF-b or Suppression of Th1 Cell-Associated Cytokines It has previously been shown that CD4 + T cell production of TGF-b is crucial for Th17 cell development in vivo (Li et al., 2007) . Given that regulatory T cells are a source of TGF-b in vitro (Veldhoen et al., 2006a) , it seemed likely that they could also be the source of TGF-b in vivo. To restrict TGF-b deficiency to the regulatory T cell population, Tgfb1 f/n mice were crossed with Figures 5C and 5D , and data not shown), suggesting that the defect was specific to Th17 cell induction. Treg cell deficiency has been reported to enhance IFN-g, but we did not consistently observe this, most probably because of the rapid expansion of Treg cells in our model compared to longer-lasting antibody or genetic depletions. Both IL-12 and IFN-g are known to inhibit Th17 cell induction (McGeachy and Cua, 2008) , and we hypothesized that Treg cells may reduce production of these Th1 cell-associated cytokines to allow Th17 cell priming. However, mRNA analysis of CD11c + dendritic cells isolated from draining LN cells day 3 postimmunization did not show any difference in IL-12p35 nor of IL-23 in the presence or absence of Treg cells ( Figure S2A ). Furthermore, administration of neutralizing anti-IFN-g was unable to restore IL-17 production ( Figure 5E ), and IFN-gR-deficient OT-II cells also showed impaired IL-17 production in the absence of Treg cells ( Figure S2B ). Use of IL-12p35-deficient Foxp3.luciDTR4 recipients did not restore IL-17 production after Treg cell depletion ( Figure S2C ). Therefore, the reduced IL-17 could not be attributed to inhibitory effects of enhanced IFN-g production when Treg cells were depleted. 
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IgG1 α-IL-2 IgG1 α-IL-2 Treg Cells Promote Th17 Cell Development by Regulating IL-2 Treg cells are highly dependent on IL-2 for maintenance and expansion (Setoguchi et al., 2005) . IL-2 has also been shown to regulate Th17 cell induction (Laurence et al., 2007; Lohr et al., 2006) . Treg cells are early responders to IL-2 produced by other activated T cells in vivo (O'Gorman et al., 2009) , and their consumption of IL-2 has been proposed as a mechanism of regulation (Barthlott et al., 2005; de la Rosa et al., 2004; Pandiyan et al., 2007) . We therefore tested whether IL-2 blockade could impact Th17 cell induction in relation to Treg cells. Neutralizing IL-2 antibody was administered for 5 days from immunization of OT-II-transferred mice, via a protocol previously demonstrated to block IL-2 activity on Treg cells (Setoguchi et al., 2005; Suffner et al., 2010) . IL-2 neutralization itself did not alter the percentage of IL-17 producers in control mice. However, when Treg cells were depleted at the time of immunization, IL-2 neutralization significantly increased the percentage of IL-17-producing cells ( Figure 6A ), as well as the absolute numbers of IL-17 + cells, restoring these to similar numbers as observed in control mice ( Figure 6B ). As expected, Foxp3 + Treg cell frequencies were reduced when IL-2 was neutralized in control mice ( Figure 6C ), confirming the known importance of IL-2 for Treg cell homeostasis (Furtado et al., 2002; Malek et al., 2002; Setoguchi et al., 2005) . However, the most dramatic effect was on the rapid expansion of Treg cells after DT administration, which was almost completely inhibited when IL-2 was neutralized ( Figure 6C ). Treg cells could regulate IL-2 in two ways: by inhibiting IL-2 production (Thornton and Shevach, 1998) or by consuming IL-2 (Barthlott et al., 2005; de la Rosa et al., 2004; Pandiyan et al., 2007) by virtue of their constitutive expression of highaffinity IL-2 receptor. Serum IL-2 was not consistently detectable by enzyme-linked immunosorbent assay (ELISA) on day 3 or day 7 postimmunization. We therefore analyzed the frequency of IL-2-producing OT-II cells on day 3 postimmunization by using conventional phorbol myristate acetate (PMA) and ionomycin stimulation ( Figure S3A ) as well as stimulation with OVA(323-339) peptide for 4 hr, followed by IL-2 secretion capture assay ( Figure 6D ). Figure S3B shows IL-2 expression in non-OT-II CD4 + T cells, which were used to set the analysis gates. Both of these methods confirmed that Treg cell depletion did not result in enhanced IL-2 production by recently activated T cells. In fact, the majority of the OT-II cells were observed to produce IL-2 regardless of whether Treg cells were present or not, as we have observed before at early time points during Th17 cell development (McGeachy et al., 2009 ). We then further tested IL-2 secretion directly ex vivo, as well as after only 1 hr peptide stimulation, at both 24 hr and 3 days postimmunization.
Again, there was no difference in the frequency of IL-2-producing OT-II cells ( Figure 6E ) or of OT-II À cells ( Figure S3C ).
Finally, we isolated total CD4 + and CD4 À cells from draining LN cells at 24 hr and 3 days postimmunization and performed quantitative reverse-transcriptase polymerase chain reaction (RT-PCR), which again showed no difference in total IL-2 mRNA between control and Treg cell-depleted mice ( Figure 6F ). Therefore, we conclude that Treg cells did not regulate IL-2 production by developing Th17 cells in vivo. IL-2 receptor engagement results in phosphorylation of signal transducer and activator of transcription-5 (pSTAT5), and pSTAT5 was required for inhibition of IL-17 by IL-2 (Laurence et al., 2007) . We therefore compared ex vivo pSTAT5 in OT-II cells on day 3 postimmunization in the presence or absence of Treg cells. The frequency of pSTAT5-positive OT-II cells was increased when Treg cells had been depleted ( Figure 6G ). The high-affinity IL-2 receptor subunit CD25 is upregulated in recently activated T cells in response to IL-2 signaling in a feed-forward manner (Kim et al., 2001) . Corresponding with increased pSTAT5, CD25 expression was also increased in the absence of Treg cells ( Figure 6H ). We also observed pSTAT5 expression in Foxp3 + T cells at day 3 postimmunization (data not shown), confirming previous reported data ( O'Gorman et al., 2009) . Because other factors such as IL-7 can activate STAT5, and CD25 is also upregulated in response to CD28 costimulation, we next confirmed that the changes observed after Treg cell depletion were due to enhanced IL-2. When we analyzed IL-17 production at day 3, the effect of IL-2 neutralization was even more marked than at day 7 ( Figure 6I ). When anti-IL-2 was administered during Treg cell depletion and immunization, both pSTAT5 and CD25 expression were markedly decreased compared to isotype control-treated mice ( Figures 6J and 6K) . Taken together, these data confirmed that one of the mechanisms through which Treg cells promote Th17 cell development was the consumption of IL-2, thereby reducing upregulation of CD25 and activation of the STAT5 pathway. Li et al. (2007) initially showed that T cells are a main source of TGF-b for Th17 cell induction in vivo, although they did not dissect which T cell populations are required. In vitro data suggested that Treg cells support Th17 cell development and that this may be through production of TGF-b (LeibundGut-Landmann et al., 2007; Veldhoen et al., 2006a) . Cotransfer of Treg cells with naive T cells in graft-versus-host disease or neo-self autoimmune models results in increased frequencies of Th17 cells, although the mechanism was not clear from either study ( Lohr et al., 2006; Vokaer et al., 2010) . We found the same enhancement of IL-17 by cotransferred Treg cells by using a Th17 cell-inducing immunization protocol. Our data now further show that Foxp3 + regulatory T cells are required for the full generation of Th17 cell responses in vivo. However, we find that TGF-b production by Treg cells is not required in vivo, in contrast to suggestions from in vitro data.
DISCUSSION
Recent data argue that TGF-b is dispensable if Th1 cell and Th2 cell responses are inhibited (Das et al., 2009) . Treg cells could certainly also perform this function, either directly or indirectly via actions on antigen-presenting cells (APC). However, we did not observe any effect of blocking Th1 cell-associated cytokines IL-12 or IFN-g, nor did we find any evidence to support the hypothesis that APC function was altered to favor a Th1 cell rather than Th17 cell response. It was unexpected that depletion of Treg cells did not lead to increased production of IFN-g in our model. An increased activation state was observed in the recipient CD4 + Foxp3 -T cell population, with greater proportions of cells expressing CD44. Increased activation of CD4 + T cells was also reported when Treg cells were depleted in nonimmunized mice (Suffner et al., 2010) . However, we did not consistently see an increase in IFN-g, nor did IFN-g contribute to the reduced IL-17 when Treg cells were depleted. Our model is optimized toward Th17 cell induction, so few IFN-g + cells are routinely observed (McGeachy et al., 2009) . Perhaps more importantly, in this system Treg cells are not continuously depleted and numbers return to normal within 1 week. Given the high expression of CD44 by these recently expanded Treg cells, it could be hypothesized that it is this return to active duty of the Treg cell population that limits an overexuberant Th1 cell response.
The cytokine IL-2 is produced by T cells early after activation and has been shown to inhibit the generation of Th17 cells (Laurence et al., 2007) . The partial restoration of IL-17 production when IL-2 was neutralized showed that regulation of IL-2 is one of the previously unappreciated mechanisms of action of Foxp3 + Treg cells in promoting Th17 cells in vivo. The percentage of IL-17-producing cells was not fully restored compared to controls, although numbers were similar, suggesting that there may be further additional mechanisms by which Treg cells promote Th17 cell development at this early stage.
Treg cells could regulate IL-2 by two mechanisms: inhibition of IL-2 production by activated T cells (Thornton and Shevach, 1998) or consumption of IL-2 to limit activated T cell exposure to IL-2 (Barthlott et al., 2005; Pandiyan et al., 2007) . It has also been shown that both mechanisms could operate in the same system in vitro (Barthlott et al., 2005) . We were unable to detect an increase in serum IL-2, although concentrations were below assay sensitivity for most mice tested (data not shown). However, we were able to show that Treg cell depletion did not result in altered IL-2 production ex vivo or in response to general or antigen-specific ex vivo activation. The propensity of OT-II cells to produce IL-2 under this protocol further supports the need for a mechanism to regulate IL-2 signaling in these cells in order to allow Th17 cell development.
O 'Gorman et al. (2009) have recently demonstrated that Foxp3 + Treg cells rather than activated T cells are first responders to, in other words consumers of, IL-2 after immunization. We did confirm that a proportion of Foxp3 + cells are pSTAT5 + in our model (data not shown). Furthermore, the reduced expansion of Treg cells after DT administration under IL-2-neutralizing conditions supports the hypothesis that Treg cells are consuming IL-2. In this regard, one could speculate that the more rapid expansion of Treg cells in mice immunized with OVA-CFA compared to naive mice is at least in part mediated by the increased IL-2 production that occurs when T cells are activated.
A clearer link between Treg cell depletion and increased IL-2 signaling in developing Th17 cells came from analysis of ex vivo pSTAT5 and CD25 expression. During early activation, IL-2 signaling results in further upregulation of the high-affinity subunit of its own receptor, CD25 (Kim et al., 2001; Malek, 2008) . When Treg cells were depleted, both pSTAT5 and CD25 were increased around 2-fold in the OT-II population. This effect could be blocked by neutralizing IL-2, confirming that it was specific to IL-2 and not because of other activation signals or cytokines. These results, along with the IL-2 expression data, led us to conclude that it is more likely that Treg cell consumption of IL-2 supported early Th17 cell development.
After Treg cell depletion, the reduced frequency of IL-17-producing OVA-specific cells in the dLN cells correlated well with reduced frequency of these cells in the blood at day 10. Hence, the effector response was impaired at the population level. By using this OT-II transfer system of Th17 cell activation in vivo, we have previously shown similar reduction of IL-17 + IL-23R-deficient effector cells in the blood correlating with reduced ability to induce inflammation in the DTH response (McGeachy et al., 2009) . In seeming contrast to our results, Sparwasser and colleagues had previously shown enhanced DTH responses in their DEREG mice when Treg cells are depleted (Lahl et al., 2007) . However, they used a hapten-based model without CFA, most probably not Th17 cell dependent, and, perhaps more importantly, Treg cells are continuously absent up to and including the point of DTH challenge. In our mice, Treg cell percentages were similar to wild-type at the time of DTH challenge, and therefore our data do not directly contradict the conclusion of Sparwasser and colleagues that Treg cells modulate tissue-specific inflammation. Rather, we examined the effects on Th17 cells when Treg cells are absent only during primary challenge. Foxp3 + Treg cells have been shown to convert into Th17 cells under inflammatory conditions (Xu et al., 2007 (Bending et al., 2009; Martin-Orozco et al., 2009 ). We did not observe this, but we used T cells that had undergone two rounds of stimulation with TGF-b and IL-6 in vitro and were transferred into lymphoid-sufficient hosts. This concurs with the recent study from Nurieva et al. (2009) showing that transfer into a lymphopenic environment results in greater Th1 cell conversion than transfer into lymphoidsufficient hosts. Importantly, Treg cell depletion on day 4 postimmunization had little effect on IL-17 induction. Therefore we conclude that the time frame in which Treg cells promote Th17 cell development and/or function is probably quite short, fitting with our previous data showing that IL-23 signals are crucial from day 4 and 5 of the immune response to promote subsequent Th17 cell effector cell differentiation (McGeachy et al., 2009 ). This also allows for the possibility that Treg cells may inhibit Th17 cell responses during the later phase of inflammation. In many of the inflammatory disease models now associated with Th17 cells, including experimental autoimmune encephalitis (EAE) and arthritis, Treg cells have been shown to limit immunopathology: the depletion of Treg cells results in exacerbated disease or reduced threshold for disease initiation (Sakaguchi and Powrie, 2007) . It may seem surprising that Treg cells would promote inflammatory cells. However, our finding that Treg cell promotion of Th17 cell development was mainly restricted to the initial few days after immunization suggests that Treg cells will not continually promote Th17 cell inflammatory function. These observations are also in agreement with findings from several models of inflammation caused by deficiency of Treg cells: this type of inflammation is most often dominated by a Th1 cell response. One notable exception is the IL-2-deficient mouse, in which Treg cells are almost nonexistent; in this mouse, Th17 cells dominate the overwhelming inflammatory disease. In addition, it should be noted that use of anti-CD25 to deplete Treg cells could also allow Th17 cell development by blocking IL-2 signaling.
The immune system is a constant balancing act, and this seems to be yet another example: by consuming IL-2, Treg cells protect developing Th17 cells from IL-2's inhibitory effects, but in doing so the Treg cells are also promoting their own expansion (Furtado et al., 2002) . Because the stimulus of inflammation (in the case of infection) is controlled by the Th17 cell response, the expanded Treg cells are now better able to do their part to control the inflammation and restore homeostasis. In the case of chronic autoimmune inflammation, it is clear that this process has become dysregulated, and therapeutic interventions become necessary to restore balance.
EXPERIMENTAL PROCEDURES Mice
Foxp3.luciDTR4 and Foxp3.luciDTR5 mice were generated and provided by G. Hammerling, DKFZ, Heidelberg, Germany. Mice were maintained on a heterozygous background and screened on basis of GFP expression. 
Reagents
The following flow cytometry antibodies were purchased from BD Biosciences: CD4 (RM4-5), CD45.1 (A20), CD44 (IM7), IFN-g (XMG1.2), IL-17 (TC11-18H10), and pSTAT5(pY694). Intracellular cytokine staining was performed with Cytofix-cytoperm kit from BD according to the manufacturer's instructions. pSTAT5 staining was performed with BD Phosflow kit according to the manufacturer's instructions. We purchased from eBioscience Foxp3 (FJK-16 s), used with Foxp3 staining kit from eBioscience according to the manufacturer's instructions. Anti-IL-2 (S4B6) was obtained from BioXCell; anti-IFN-g (XMG1.2) and isotype control (rat IgG1) Abs were generated inhouse. OVA(323-339) was obtained from Biosynthesis Inc (Lewisville, TX). LN cells were cultured in complete medium (RPMI media containing 10% FCS, supplemented with Pen-Strep, L-glutamine, HEPES, sodium pyruvate, and 2-ME) with 50 ng/ml PMA and 500 ng/ml ionomycin (both Sigma-Aldrich) in the presence of Golgiplug (BD Biosciences) for 4 hr followed by staining and analysis by flow cytometry. For pSTAT5 analysis, 3 3 10 6 CD45.1 + OT-II CD4 + CD25-depleted T cells were transferred intravenously into CD45.2 + wild-type or Foxp3.lucDTR recipient mice, which were immunized as before. Draining LN cells were removed on day 3 and single-cell suspensions were immediately obtained by mashing into BD Phosflow Fix buffer. After a further 10 min incubation at 37 C, cells were washed and permeabilized and antibody staining was performed as per BD Phosflow manufacturer's instructions. IL-2 secretion was detected on day 3 by stimulating the lymph node cells for 4 hr with 5 mg/ml OVA(323-339), followed by detection of secreted IL-2 with the IL-2 secretion assay detection kit (Miltenyi Biotec).
Treg Cell Depletion
Mice received two injections of Diphtheria toxin isolated from corynebacterium diphtheriae (Sigma-Aldrich, MO) in PBS given 1 day apart by the intraperitoneal route, at a dose of 15 ng per g body weight.
In Vitro Th17 Cell Induction and Transfer OT-II LN and spleen cells were stimulated with OVA(323-339) in the presence of 10 ng/ml TGF-b, 100 ng/ml IL-6 (both from R&D), 5 mg/ml anti-IFN-g (XMG1.2), and 2.5 mg/ml anti-IL-2 (JES6-1A12) in RPMI media containing 10% FCS, supplemented with Pen-Strep, L-glutamine, HEPES, sodium pyruvate, and 2-ME. Cells were restimulated under the same conditions with the addition of CD4-depleted splenocytes on day 6 of culture. On day 9, IL-17 production was assessed by intracellular cytokine staining after stimulation with PMA and ionomycin for 4 hr. CD4 + cells were enriched before transfer by positive selection with anti-CD4 microbeads (Miltenyi Biotec) according to manufacturer's instructions.
Delayed Type Hypersensitivity
Immunized recipients of OT-II cells were challenged in one hind footpad with 100 mg ovalbumin in saline; the contralateral hind footpad was injected with saline only. Foot thickness was measured 24 hr later with calipers (Mitutoyo), and data are shown as increase in OVA-challenged foot thickness over the saline control for the same mouse.
Statistics
Statistical analysis was done by Student's t test (two groups) or one-way ANOVA (more than two groups) with Graphpad Prism software. Where shown, error bars indicate standard deviation.
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